Tetraphase Pharmaceu (TTPH) Stock Price, Forecast & Analysis
USA - NASDAQ:TTPH -
TTPH Key Statistics, Chart & Performance
The current stock price of TTPH is 2.2 null. In the past month the price decreased by -14.73%. In the past year, price decreased by -68.12%.
TTPH Latest News, Press Relases and Analysis
About TTPH
Company Profile
Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.
Company Info
Tetraphase Pharmaceu
480 ARSENAL WAY
WATERTOWN MA 02472
CEO: Larry Edwards
Phone: 617-715-3600
Tetraphase Pharmaceu / TTPH FAQ
What does TTPH do?
Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.
What is the current price of TTPH stock?
The current stock price of TTPH is 2.2 null. The price decreased by -3.51% in the last trading session.
Does Tetraphase Pharmaceu pay dividends?
TTPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of TTPH stock?
TTPH has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for TTPH stock?
Tetraphase Pharmaceu (TTPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.46).
Who owns Tetraphase Pharmaceu?
You can find the ownership structure of Tetraphase Pharmaceu (TTPH) on the Ownership tab.
TTPH Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TTPH. When comparing the yearly performance of all stocks, TTPH is a bad performer in the overall market: 64.88% of all stocks are doing better.
TTPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TTPH. Both the profitability and financial health of TTPH have multiple concerns.
TTPH Financial Highlights
Over the last trailing twelve months TTPH reported a non-GAAP Earnings per Share(EPS) of -18.46. The EPS decreased by -126.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -798.18% | ||
| ROA | -167.91% | ||
| ROE | N/A | ||
| Debt/Equity | 0.06 |